导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 14.01% | 498/4773 |
| 近一周 | -3.24% | 3929/5462 |
| 近一月 | -7.39% | 3807/5421 |
| 近一季 | -13.91% | 4095/5209 |
| 近半年 | 5.91% | 736/4920 |
| 近一年 | 22.29% | 346/4366 |
| 近两年 | 154.54% | 176/2954 |
| 近三年 | 101.00% | 132/2253 |
| 成立以来 | 79.57% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.24% 1002/4961 |
40.38% 777/5312 |
- - |
- - |
| 2025 | 59.62% 219/4813 |
-1.53% 2684/3635 |
6.24% 475/4076 |
49.32% 342/4524 |
2.18% 1058/4813 |
| 2024 | 16.17% 838/3463 |
-0.16% 1080/2808 |
-5.39% 1711/3014 |
15.56% 1682/3129 |
6.42% 514/3463 |
| 2023 | 4.67% 221/2656 |
36.69% 48/2280 |
-0.78% 416/2385 |
-16.67% 2259/2515 |
-7.38% 2133/2655 |
| 2022 | -27.97% 1518/2207 |
-21.26% 1610/1919 |
-1.39% 1718/2016 |
-14.51% 1108/2113 |
8.50% 261/2208 |
| 2021 | 9.00% 461/1822 |
-6.75% 1037/1255 |
11.17% 390/1330 |
-5.34% 796/1466 |
11.08% 93/1822 |
| 2020 | 21.76% 685/1250 |
-0.89% 196/1028 |
21.10% 247/1067 |
1.98% 1015/1164 |
-0.52% 1078/1184 |
| 2019 | 45.73% 146/1092 |
38.37% 65/754 |
-9.36% 647/804 |
6.91% 109/850 |
8.68% 298/918 |
| 2018 | -29.50% 454/834 |
- - |
- - |
- - |
-12.86% 488/691 |
| 2017 | 14.53% 255/714 |
- - |
- - |
- - |
- - |
| 2016 | -19.79% 437/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方中证互联网指数(LOF)A VS. 长安沪深300非周期A(740101) |